1. Home
  2. KOPN vs LCTX Comparison

KOPN vs LCTX Comparison

Compare KOPN & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kopin Corporation

KOPN

Kopin Corporation

HOLD

Current Price

$2.42

Market Cap

424.9M

Sector

Technology

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.75

Market Cap

393.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOPN
LCTX
Founded
1984
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
424.9M
393.9M
IPO Year
1992
N/A

Fundamental Metrics

Financial Performance
Metric
KOPN
LCTX
Price
$2.42
$1.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$4.25
$4.25
AVG Volume (30 Days)
3.6M
2.4M
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$45,602,295.00
$10,816,000.00
Revenue This Year
$2.28
N/A
Revenue Next Year
$29.71
$176.00
P/E Ratio
N/A
N/A
Revenue Growth
3.02
24.05
52 Week Low
$0.71
$0.37
52 Week High
$4.16
$2.09

Technical Indicators

Market Signals
Indicator
KOPN
LCTX
Relative Strength Index (RSI) 37.94 50.42
Support Level $2.24 $1.66
Resistance Level $2.50 $1.99
Average True Range (ATR) 0.23 0.12
MACD -0.02 -0.02
Stochastic Oscillator 22.22 27.27

Price Performance

Historical Comparison
KOPN
LCTX

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: